Navigation Links
World-first swine-flu vaccine trial reveals one dose provides 'strong immune response'

Results from the first swine-flu vaccine trials taking place in Leicester reveal a strong immune response after just one dose.

The pilot study, run by the University of Leicester and Leicester Hospitals, was trialled with 100 healthy volunteers, aged between 18 and 50.

Dr Iain Stephenson, who led the trial at the Leicester Royal Infirmary, said: "The clinical trial of Novartis MF59-adjuvanted cell-based A (H1N1) vaccine indicates that the "swine flu" vaccine elicits a strong immune response and is well-tolerated.

"Results showed that the serum antibody responses were highest among subjects who received two doses of vaccine, however a single vaccine dose also induced responses associated with protection against influenza.

"The findings showed that it is possible to induce protective antibody against A(H1N1) infection within two weeks of administration of a single low-dose adjuvanted vaccine."

Non-adjuvanted formulations were not evaluated in this part of the study and will be evaluated shortly

The trial evaluated the tolerability and immunogenicity of the vaccine, and tested different schedules of vaccination, in terms of time between vaccinations. The vaccine schedule was one or two doses of 7.5μg MF-59 adjuvanted surface-antigen A/California/2009 vaccine derived from cell-culture.

Dr. Stephenson, of the Department of Infection, Immunity and Inflammation at the University of Leicester is a clinical senior lecturer at the University, and a consultant in infectious diseases at the University Hospitals of Leicester NHS Trust. He said: "The aim of the trial was to find out how many doses and what type of vaccine is needed to give protection. These initial results should help to plan vaccination campaigns in the autumn, including doses and timings. We concluded that the MF59-adjuvanted A(H1N1) vaccine of low antigen content was well tolerated and generated antibody responses associated with protection against influenza, even after a single dose."

"The results suggest that one vaccine dose may be sufficient to protect against the A(H1N1) swine flu, rather than two. Larger trials are already underway around the world. Timings on when the vaccine will be available to governments will depend on the results of these clinical trials, and approvals by regulatory authorities''

The research found the vaccine is well tolerated with pain at the injection site the most frequent adverse event.

Additional pivotal trials with both cell culture and traditional egg based vaccines under way around the world that will include more than 6000 adults and children.

Previous research had indicated that two doses of the vaccine would be needed against swine flu. You can access earlier stories here:


Contact: Ather Mirza
University of Leicester

Related biology news :

1. Study of African traditional medicine will begin world-first clinical trial
2. World-first to predict premature births
3. A world-first in solar technology unveiled at Concordia University
4. Britains first swine-flu trials under way
5. Possible hepatitis C vaccine
6. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
7. New nanoparticle vaccine is more effective but less expensive
8. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
9. Influenza vaccine causes weaker immune response for children of rural Gabon than in semi-urban areas
10. An Alzheimers vaccine?
11. Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine
Post Your Comments:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
Breaking Biology Technology: